Abuse Liability of Reduced Nicotine Content Cigarettes in the Context of Concurrent E-Cigarette Use

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-05-01

Study Completion Date

2021-07-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Three hundred-twenty (320) adult smokers of menthol or non-menthol combustible cigarettes will be recruited and randomly assigned to one of five groups (n=64/group), who will be asked to switch for 12 weeks to ad libitum use of combustible cigarettes (matched to subjects' menthol preference) containing either 0.4, 1.4, 2.5, 5.6 or 16.9 mg nicotine (standardized nicotine yields ranging from 0.02-0.80 mg/cigarette), respectively. Each group will include 32 heavy (≥ 20 cigarettes/day), and 32 light smokers (≤10 cigarettes/day), who are hypothesized to be more sensitive to nicotine's reinforcing effects. Participants will also have free access to nicotine-containing e-cigarettes (JUUL) throughout the 12-week period. Abuse liability of combustible cigarettes will be assessed by behavioral (cigarettes/day, time to first cigarettes), self-report (rewarding effects, withdrawal symptoms) and biochemical indices (expired air carbon monoxide, cotinine blood sampling).

In laboratory sessions, we will measure nicotine thresholds for detecting and recognizing the addictive, rewarding effects of smoking. This study is designed to help the FDA identify a target nicotine threshold that will not attract young people to smoking or induce relapse in former smokers. Additionally, we will determine the level of cigarette nicotine reduction that will be tolerated without inducing dissatisfaction in smokers, information that is relevant to the FDA for designing a stepwise nicotine reduction policy that can be implemented without widespread objections. The knowledge gained from this project will greatly increase our knowledge of nicotine addiction and will help frame an FDA policy relating to the regulation of the nicotine content of tobacco. Ultimately, a well-designed nicotine reduction policy has the potential to greatly reduce the enormous toll of death and disease caused by cigarette smoking.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effects of Menthol as Delivered by an Electronic Cigarette on the Desirability of Nicotine in Tobacco Users

NCT02102100

Nicotine Dependence

COMPLETED NA

The Role of Nicotine and Non-Nicotine Alkaloids in E-Cigarette Use and Dependence

NCT02590393

Nicotine Dependence

COMPLETED PHASE1/PHASE2

Adaptive Use of Nicotine Substitution to Maintain Smoking Reduction/Abstinence in Nicotine Responders

NCT06554873

Smoking Cessation Harm Reduction

COMPLETED PHASE3

Effects of Menthol in E-cigarettes on Smoking Behaviors

NCT04521647

Nicotine Dependence

COMPLETED PHASE1

Comparisons of Nicotine-free Cigarettes, Extra Low Nicotine Cigarettes vs. Medicinal Nicotine

NCT00777569

Tobacco Dependence

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nicotine Addiction Cigarette Smoking

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

0.40mg Nicotine Cigarette w/ e-Cigarette

Participants will be assigned to smoke 0.40mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.

Smoking research cigarettes with e-cigarette

Group Type ACTIVE_COMPARATOR

Smoking research cigarettes with e-cigarette

Intervention Type DRUG

Smoking research cigarettes with varying levels of nicotine with unlimited access to 15 mg/ml nicotine-containing e-cigarettes.

1.40mg Nicotine Cigarette w/ e-Cigarette

Participants will be assigned to smoke 1.40mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.

Smoking research cigarettes with e-cigarette

Group Type ACTIVE_COMPARATOR

Smoking research cigarettes with e-cigarette

Intervention Type DRUG

Smoking research cigarettes with varying levels of nicotine with unlimited access to 15 mg/ml nicotine-containing e-cigarettes.

2.50mg Nicotine Cigarette w/ e-Cigarette

Participants will be assigned to smoke 2.50mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.

Smoking research cigarettes with e-cigarette

Group Type ACTIVE_COMPARATOR

Smoking research cigarettes with e-cigarette

Intervention Type DRUG

Smoking research cigarettes with varying levels of nicotine with unlimited access to 15 mg/ml nicotine-containing e-cigarettes.

5.60mg Nicotine Cigarette w/ e-Cigarette

Participants will be assigned to smoke 5.60mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.

Smoking research cigarettes with e-cigarette

Group Type ACTIVE_COMPARATOR

Smoking research cigarettes with e-cigarette

Intervention Type DRUG

Smoking research cigarettes with varying levels of nicotine with unlimited access to 15 mg/ml nicotine-containing e-cigarettes.

16.9mg Nicotine Cigarette w/ e-Cigarette

Participants will be assigned to smoke 16.9mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.

Smoking research cigarettes with e-cigarette

Group Type ACTIVE_COMPARATOR

Smoking research cigarettes with e-cigarette

Intervention Type DRUG

Smoking research cigarettes with varying levels of nicotine with unlimited access to 15 mg/ml nicotine-containing e-cigarettes.

Halo G6 & Tribeca e-liquid

Difference detection assessments.

Nicotine discrimination thresholds

Group Type EXPERIMENTAL

Nicotine discrimination thresholds

Intervention Type DRUG

Measure of nicotine thresholds for detecting and recognizing the addictive, rewarding effects of smoking.

Spectrum Research Cigarette

Difference detection assessments.

Nicotine discrimination thresholds

Group Type EXPERIMENTAL

Nicotine discrimination thresholds

Intervention Type DRUG

Measure of nicotine thresholds for detecting and recognizing the addictive, rewarding effects of smoking.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Smoking research cigarettes with e-cigarette

Smoking research cigarettes with varying levels of nicotine with unlimited access to 15 mg/ml nicotine-containing e-cigarettes.

Intervention Type DRUG

Nicotine discrimination thresholds

Measure of nicotine thresholds for detecting and recognizing the addictive, rewarding effects of smoking.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Spectrum Cigarettes JUUL e-Cigarette Halo G6 with Tribeca e-liquid

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is healthy as judged by the Investigator based on all available assessments from the Screening Period (e.g., safety laboratory, vital signs, physical examination, ECG, concomitant medications and medical history).
2. Subject smokes on average four days a week for the last 12 months.
3. Subject has no intention of quitting smoking within the next 90 days.
4. Owns a smart phone with text message and data capabilities.
5. Willingness to use and ability to operate e-cigarettes.
6. Willingness to smoke Research Cigarettes.

Exclusion Criteria

1. Any medical or psychiatric condition (or associated symptoms or medications) determined by a medical professional to be severe enough to be disruptive to the study.
2. Severe or uncontrolled psychiatric disease with the exception of anxiety disorders, obsessive-compulsive disorder (OCD) and attention deficit hyperactivity disorder (ADHD);
3. Pregnant or nursing (by self-report) or positive pregnancy test;
4. Daily use of:

1. Experimental (investigational) drugs that are unknown to subject;
2. Smokeless tobacco (chewing tobacco, snuff), cigars, pipes and hookah;
3. e-cigarettes;
5. Use in the past 30 days of nicotine replacement therapy or other smoking cessation product
6. Positive drug screen for cocaine

Minimum Eligible Age

21 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes